Enzalutamide for prostatic neoplasms

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 2 trial. Mid-stage trial in people. As of 19 Nov 2026, from 2 registered trials.

Why this status

  1. 22 May 2015: Trial registered, NCT02452008
  2. 3 May 2016: Trial started, NCT02452008
  3. 18 Jan 2019: Trial registered, NCT03809000
  4. 15 Apr 2019: Trial started, NCT03809000

The trials

NCT02452008: Study of TGF-β Receptor Inhibitor Galunisertib (LY2157299) and Enzalutamide in Metastatic Castration-resistant Prostate Cancer

State
Under way
Phase
Phase 2
People
60 taking part
Started
3 May 2016
Primary completion
8 Dec 2025
Arms
Arm 2: Enzalutamide alone
Results
Posted on the registry
  1. 22 May 2015: Trial registered
  2. 3 May 2016: Trial started
  3. 6 Nov 2026: Trial results posted

NCT03809000: A Study of Salvage Radiotherapy With or Without Enzalutamide in Recurrent Prostate Cancer Following Surgery

State
Under way
Phase
Phase 2
People
188 taking part
Started
15 Apr 2019
Primary completion
7 Apr 2023
Arms
Salvage Radiation Therapy + Enhanced ADT
Results
Posted on the registry
  1. 18 Jan 2019: Trial registered
  2. 15 Apr 2019: Trial started
  3. 16 Oct 2024: Trial results posted

How the status changed

  1. 19 Nov 2026: First set: Phase 2 trial

About the treatment

Kind of treatment: Drug.

Also known as Enzalutamide 40mg, Xtandi.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.